 BetterLife Pharma Inc CSE:BETR, OTCQB:BETRF, a biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, revealed that it has obtained additional positive data confirming the anti-depressant activity of its lead compound 2-bromo-LSD BETR-001 in preclinical models of depression. The study is part of the Vancouver-based companys collaboration with the laboratory of Dr Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. 